• Vaccine Name: M72/AS01E
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: The vaccine contains M72 fusion protein, which is made from two Mycobacterium tuberculosis antigens: Mtb32A and Mtb39A (Tait et al., 2019).
• PepA gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Tait et al., 2019).
  • Detailed Gene Information: Click Here.
• PPE18 gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Tait et al., 2019).
  • Detailed Gene Information: Click Here.
• Adjuvant: AS01 vaccine adjuvant
  • Adjuvant name: AS01 vaccine adjuvant
  • VO adjuvant ID: VO_0005534
  • Description: AS01 is the adjuvant in this vaccine that enhance antigen presentation and promote strong T-cell and antibody responses (Tait et al., 2019).
• Preparation: The TB proteins are genetically fused into one protein (M72), then purified and formulated with the AS01E adjuvant system (Tait et al., 2019).
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Vaccination Protocol: Participants are immunized 2 doses spaced by one month (Tait et al., 2019).
• Immune Response: The vaccine induces a strong immune response characterized by activation of antigen-specific CD4? and CD8? T cells, increased production of cytokines such as IFN-?, TNF-?, and IL-2, and the development of long-lasting memory T cells, along with enhanced antibody production (Tait et al., 2019).
• Side Effects: Injection site reactions and flu like symptoms (Tait et al., 2019).